On the importance of estimating renal function for cardiovascular risk assessment

Julian Segura, Luis M. Ruilope, Alberto Zanchetti

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Microalbuminuria has been shown to predict an increased probability of suffering a cardiovascular event or death. It has also been shown to be decreased by antihypertensive therapy and in particular by drugs counteracting the effects of angiotensin II. In this issue of Journal of Hypertension data, from the LIFE study, are reported indicating for the first time that a decrease in urinary albumin excretion rate is accompanied by a significant decrease in cardiovascular events. This evidence is of great relevance because it constitutes the first evidence showing that regression of an intermediate end-point, microalbuminuria, ensures a better cardiovascular prognosis.

Original languageEnglish
Pages (from-to)1635-1639
Number of pages5
JournalJournal of Hypertension
Volume22
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Angiotensin II
Antihypertensive Agents
Albumins
Hypertension
Kidney
Pharmaceutical Preparations
Therapeutics

Keywords

  • Arterial hypertension
  • Cardiovascular risk
  • LIFE study
  • Microalbuminuria

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

On the importance of estimating renal function for cardiovascular risk assessment. / Segura, Julian; Ruilope, Luis M.; Zanchetti, Alberto.

In: Journal of Hypertension, Vol. 22, No. 9, 09.2004, p. 1635-1639.

Research output: Contribution to journalArticle

Segura, Julian ; Ruilope, Luis M. ; Zanchetti, Alberto. / On the importance of estimating renal function for cardiovascular risk assessment. In: Journal of Hypertension. 2004 ; Vol. 22, No. 9. pp. 1635-1639.
@article{8a452bcd950047bebf6b7609ef818ba2,
title = "On the importance of estimating renal function for cardiovascular risk assessment",
abstract = "Microalbuminuria has been shown to predict an increased probability of suffering a cardiovascular event or death. It has also been shown to be decreased by antihypertensive therapy and in particular by drugs counteracting the effects of angiotensin II. In this issue of Journal of Hypertension data, from the LIFE study, are reported indicating for the first time that a decrease in urinary albumin excretion rate is accompanied by a significant decrease in cardiovascular events. This evidence is of great relevance because it constitutes the first evidence showing that regression of an intermediate end-point, microalbuminuria, ensures a better cardiovascular prognosis.",
keywords = "Arterial hypertension, Cardiovascular risk, LIFE study, Microalbuminuria",
author = "Julian Segura and Ruilope, {Luis M.} and Alberto Zanchetti",
year = "2004",
month = "9",
doi = "10.1097/00004872-200409000-00001",
language = "English",
volume = "22",
pages = "1635--1639",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - On the importance of estimating renal function for cardiovascular risk assessment

AU - Segura, Julian

AU - Ruilope, Luis M.

AU - Zanchetti, Alberto

PY - 2004/9

Y1 - 2004/9

N2 - Microalbuminuria has been shown to predict an increased probability of suffering a cardiovascular event or death. It has also been shown to be decreased by antihypertensive therapy and in particular by drugs counteracting the effects of angiotensin II. In this issue of Journal of Hypertension data, from the LIFE study, are reported indicating for the first time that a decrease in urinary albumin excretion rate is accompanied by a significant decrease in cardiovascular events. This evidence is of great relevance because it constitutes the first evidence showing that regression of an intermediate end-point, microalbuminuria, ensures a better cardiovascular prognosis.

AB - Microalbuminuria has been shown to predict an increased probability of suffering a cardiovascular event or death. It has also been shown to be decreased by antihypertensive therapy and in particular by drugs counteracting the effects of angiotensin II. In this issue of Journal of Hypertension data, from the LIFE study, are reported indicating for the first time that a decrease in urinary albumin excretion rate is accompanied by a significant decrease in cardiovascular events. This evidence is of great relevance because it constitutes the first evidence showing that regression of an intermediate end-point, microalbuminuria, ensures a better cardiovascular prognosis.

KW - Arterial hypertension

KW - Cardiovascular risk

KW - LIFE study

KW - Microalbuminuria

UR - http://www.scopus.com/inward/record.url?scp=4344698665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344698665&partnerID=8YFLogxK

U2 - 10.1097/00004872-200409000-00001

DO - 10.1097/00004872-200409000-00001

M3 - Article

VL - 22

SP - 1635

EP - 1639

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 9

ER -